Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 70, No 3 (2019)
Original paper
Submitted: 2018-10-12
Accepted: 2019-01-22
Published online: 2019-02-22
View PDF Download PDF file
Get Citation

Expression of CD9 and CD82 in papillary thyroid microcarcinoma and its prognostic significance

Taeyoung Kim1, Yonhee Kim2, Hyeong Ju Kwon3
DOI: 10.5603/EP.a2019.0009
·
Pubmed: 30794730
·
Endokrynol Pol 2019;70(3):224-231.
Affiliations
  1. Department of Physiology, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic Of
  2. Soon Chun Hyang University Hospital Seoul, Republic of Korea
  3. Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea

open access

Vol 70, No 3 (2019)
Original Paper
Submitted: 2018-10-12
Accepted: 2019-01-22
Published online: 2019-02-22

Abstract

Introduction: papillary thyroid microcarcinoma is a well-known malignant neoplasm with good prognosis. The known prognostic factors are patient’s age, multifocality, and extrathyroidal extension. CD9 and CD82, members of the tetraspanin family, are expressed in numerous cancer cells and play many roles associated with the cellular process.

Material and methods: we investigated the immunohistochemical expression of CD9 and CD82 in papillary thyroid microcarcinoma and analysed the clinicopathological and prognostic significance. For the retrospective analysis, we collected the cases of 553 PTMC patients who had undergone thyroidectomy.

Results: The group with lymph node metastasis showed higher immunostaining intensity for CD9 than the group without metastasis (p = 0.002). In multivariate analysis, high CD9 intensity (OR = 1.58 in 3+, p = 0.0025) correlated with lymph node metastasis.

Conclusion: We suggest CD9 as a predictive prognostic factor for lymph node metastasis in PTMC.

Abstract

Introduction: papillary thyroid microcarcinoma is a well-known malignant neoplasm with good prognosis. The known prognostic factors are patient’s age, multifocality, and extrathyroidal extension. CD9 and CD82, members of the tetraspanin family, are expressed in numerous cancer cells and play many roles associated with the cellular process.

Material and methods: we investigated the immunohistochemical expression of CD9 and CD82 in papillary thyroid microcarcinoma and analysed the clinicopathological and prognostic significance. For the retrospective analysis, we collected the cases of 553 PTMC patients who had undergone thyroidectomy.

Results: The group with lymph node metastasis showed higher immunostaining intensity for CD9 than the group without metastasis (p = 0.002). In multivariate analysis, high CD9 intensity (OR = 1.58 in 3+, p = 0.0025) correlated with lymph node metastasis.

Conclusion: We suggest CD9 as a predictive prognostic factor for lymph node metastasis in PTMC.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

CD9; CD82; prognosis; papillary thyroid microcarcinoma

About this article
Title

Expression of CD9 and CD82 in papillary thyroid microcarcinoma and its prognostic significance

Journal

Endokrynologia Polska

Issue

Vol 70, No 3 (2019)

Article type

Original paper

Pages

224-231

Published online

2019-02-22

Page views

1998

Article views/downloads

955

DOI

10.5603/EP.a2019.0009

Pubmed

30794730

Bibliographic record

Endokrynol Pol 2019;70(3):224-231.

Keywords

CD9
CD82
prognosis
papillary thyroid microcarcinoma

Authors

Taeyoung Kim
Yonhee Kim
Hyeong Ju Kwon

References (36)
  1. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008; 144(6): 980–987.
    CrossRefPubMed
  2. Yoon JH, Lee HS, Kim EK, et al. Short-term Follow-up US Leads to Higher False-positive Results Without Detection of Structural Recurrences in PTMC. Medicine (Baltimore). 2016; 95(1): e2435.
    CrossRefPubMed
  3. Siddiqui S, White MG, Antic T, et al. Clinical and Pathologic Predictors of Lymph Node Metastasis and Recurrence in Papillary Thyroid Microcarcinoma. Thyroid. 2016; 26(6): 807–815.
    CrossRefPubMed
  4. Shi C, Guo Y, Lv Y, et al. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors. PLoS One. 2016; 11(12): e0167414.
    CrossRefPubMed
  5. Lim DJ, Baek KH, Lee YS, et al. Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid. 2007; 17(9): 883–888.
    CrossRefPubMed
  6. Boucheix C, Duc GH, Jasmin C, et al. Tetraspanins and malignancy. Expert Rev Mol Med. 2001; 2001: 1–17.
    CrossRefPubMed
  7. Lee J, Byun HJ, Lee MS, et al. The metastasis suppressor CD82/KAI1 inhibits fibronectin adhesion-induced epithelial-to-mesenchymal transition in prostate cancer cells by repressing the associated integrin signaling. Oncotarget. 2017; 8(1): 1641–1654.
    CrossRefPubMed
  8. Zhang BH, Liu W, Li L, et al. KAI1/CD82 and MRP1/CD9 serve as markers of infiltration, metastasis, and prognosis in laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev. 2013; 14(6): 3521–3526.
    PubMed
  9. Wu Q, Yang Y, Wu S, et al. Evaluation of the correlation of KAI1/CD82, CD44, MMP7 and β-catenin in the prediction of prognosis and metastasis in colorectal carcinoma. Diagn Pathol. 2015; 10: 176.
    CrossRefPubMed
  10. Chen Z, Mustafa T, Trojanowicz B, et al. CD82, and CD63 in thyroid cancer. Int J Mol Med. 2004; 14(4): 517–527.
    PubMed
  11. Kwon HJ, Min SY, Park MJ, et al. Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance. Pathol Res Pract. 2014; 210(5): 285–290.
    CrossRefPubMed
  12. Jazdzewski K, Boguslawska J, Jendrzejewski J, et al. Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab. 2011; 96(3): E546–E553.
    CrossRefPubMed
  13. Master A, Wójcicka A, Piekiełko-Witkowska A, et al. Untranslated regions of thyroid hormone receptor beta 1 mRNA are impaired in human clear cell renal cell carcinoma. Biochim Biophys Acta. 2010; 1802(11): 995–1005.
    CrossRefPubMed
  14. Regina Todeschini A, Hakomori Si. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta. 2008; 1780(3): 421–433.
    CrossRefPubMed
  15. Lazo PA. Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 2007; 98(11): 1666–1677.
    CrossRefPubMed
  16. Kim KJ, Kwon HJ, Kim MC, et al. CD9 Expression in Colorectal Carcinomas and Its Prognostic Significance. J Pathol Transl Med. 2016; 50(6): 459–468.
    CrossRefPubMed
  17. Dong T, Liu Z, Zhao S, et al. The Expression of CD9 and PIK3CD is Associated with Prognosis of Follicular Lymphoma. J Cancer. 2015; 6(12): 1222–1229.
    CrossRefPubMed
  18. Huang CI, Kohno N, Ogawa E, et al. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol. 1998; 153(3): 973–983.
    PubMed
  19. Houle CD, Ding XY, Foley JF, et al. Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol. 2002; 86(1): 69–78.
    PubMed
  20. Chen Z, Gu S, Trojanowicz B, et al. Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma. World J Surg Oncol. 2011; 9: 43.
    CrossRefPubMed
  21. Yin M, Soikkeli J, Jahkola T, et al. Osteopontin promotes the invasive growth of melanoma cells by activating integrin αvβ3 and down-regulating tetraspanin CD9. Am J Pathol. 2014; 184(3): 842–858.
    CrossRefPubMed
  22. Charrin S, le Naour F, Silvie O, et al. Lateral organization of membrane proteins: tetraspanins spin their web. Biochem J. 2009; 420(2): 133–154.
    CrossRefPubMed
  23. Murayama Y, Shinomura Y, Oritani K, et al. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J Cell Physiol. 2008; 216(1): 135–143.
    CrossRefPubMed
  24. Castro-Sanchez L, Soto-Guzman A, Navarro-Tito N, et al. Native type IV collagen induces cell migration through a CD9 and DDR1-dependent pathway in MDA-MB-231 breast cancer cells. Eur J Cell Biol. 2010; 89(11): 843–852.
    CrossRefPubMed
  25. Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. Curr Opin Cell Biol. 2005; 17(5): 559–564.
    CrossRefPubMed
  26. Iwasaki T, Takeda Y, Maruyama K, et al. Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro. J Biol Chem. 2013; 288(4): 2118–2131.
    CrossRefPubMed
  27. Kamisasanuki T, Tokushige S, Terasaki H, et al. Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy. Biochem Biophys Res Commun. 2011; 413(1): 128–135.
    CrossRefPubMed
  28. Richardson MM, Jennings LK, Zhang XA. Tetraspanins and tumor progression. Clin Exp Metastasis. 2011; 28(3): 261–270.
    CrossRefPubMed
  29. Huang CL, Ueno M, Liu D, et al. MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2. Oncogene. 2006; 25(49): 6480–6488.
    CrossRefPubMed
  30. Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol. 2007; 8(1): 37–48.
    CrossRefPubMed
  31. Tang M, Yin G, Wang F, et al. Downregulation of CD9 promotes pancreatic cancer growth and metastasis through upregulation of epidermal growth factor on the cell surface. Oncol Rep. 2015; 34(1): 350–358.
    CrossRefPubMed
  32. Hwang JR, Jo K, Lee Y, et al. Upregulation of CD9 in ovarian cancer is related to the induction of TNF-α gene expression and constitutive NF-κB activation. Carcinogenesis. 2012; 33(1): 77–83.
    CrossRefPubMed
  33. Xuan H, Hu X, Huang J. Role of motility-related protein-1 in promoting the development of several types of cancer (Review). Oncol Lett. 2014; 7(3): 611–615.
    CrossRefPubMed
  34. Tang Y, Bhandaru M, Cheng Y, et al. The role of the metastasis suppressor gene KAI1 in melanoma angiogenesis. Pigment Cell Melanoma Res. 2015; 28(6): 696–706.
    CrossRefPubMed
  35. Ito Y, Yoshida H, Uruno T, et al. KAI1 expression in thyroid neoplasms: its linkage with clinicopathologic features in papillary carcinoma. Pathol Res Pract. 2003; 199(2): 79–83.
    CrossRefPubMed
  36. Risinger JI, Custer M, Feigenbaum L, et al. Normal viability of Kai1/Cd82 deficient mice. Mol Carcinog. 2014; 53(8): 610–624.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl